Drug Discovery Featured Articles & Applications

  1. Advances In Immunotherapy For Cancer
    11/29/2017

    Over the past decade, advances in oncology research have resulted in many new treatment options that include immunotherapies. This article examines these newer therapies in more detail.

  2. The Unique Needs Of The HPAPI Market: Are You Prepared?
    11/22/2017

    To take advantage of the growing HPAPI market, a company must have the proper controls in place to safely handle these potent compounds and successfully bring its drug to market.

  3. Medium Preparation For Single-Use Fermentation
    11/17/2017

    To overcome many of the challenges associated with stainless steel vessels, single‑use fermentors offer an increasingly viable alternative. 

  4. Single-Use Stirred Tank Fermentor System Performance Comparison
    11/17/2017

    The process design proven for one fermentor system is not always directly transferrable to other system formats without adaptation. Here, we compare the performance of the XDR‑500 MO fermentor with the XDR‑50 MO system.

  5. Roivant Sciences Accelerates Process Development To Speed Orphan Therapy To Market
    11/10/2017

    This case study shares the work of GE’s Fast Trak Services team to help accelerate development of a process for cGMP production of material for toxicology studies.

  6. Single-Use Workflow For Recovery Of A Domain Antibody From E. Coli Culture Feed In An Automated Manner
    11/3/2017

    This application note demonstrates the performance of the automated ÄKTA™ readyflux single-use filtration system in microfiltration applications. 

  7. Automated Ultrafiltration/Diafiltration Results With Minimized Hands-On Time
    11/3/2017

    This work describes the capabilities of ÄKTA readyflux when used in ultrafiltration/diafiltration (UF/DF) applications. The process was conducted in an automated manner based on methods created using phases predefined in the UNICORN system control software.

  8. Understanding Biomarkers For Better Drug Discovery And Development
    11/2/2017

    In collaboration with Amplion Inc., we investigated biomarker usage within 24 companies focused on immunotherapy. This article shares exciting insights from our analysis, including which biomarkers are the most popular and how those biomarkers are being utilized by each company.

  9. The Race To Phase III: A Cautionary Tale Of Scalability
    10/30/2017

    Follow the paths of two companies as they learn how a science-led, risk-based development approach yields a more successful outcome in the long run.

  10. Achieving Optimal mAb Titer and Quality
    10/25/2017

    In addition to having the optimal cell line and process, it is crucial to have the optimal cell culture medium and feed to maximize  performance potential.